ALCAM and neoplasm: In vivo tumor studies showed that KO of STC1 led to a drastically reduced tumor growth rate, significantly downregulated CSC markers (CD44 and CD166) on the surface of tumor cells, and reduced CD44+/CD166+ CSC-like cell populations within the general A549 tumor cell population.